We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Molecular Test Detects Active Tuberculosis in HIV Patients

By LabMedica International staff writers
Posted on 11 Nov 2013
A major impediment to tuberculosis control in Africa is the difficulty in diagnosing active tuberculosis (TB), particularly in the context of human immunodeficiency virus (HIV) infections. More...


A set of RNA transcriptional signatures expressed in the blood of patients might provide the basis of a diagnostic test that can distinguish active TB from latent TB (LTBI), including from other diseases that have similar clinical symptoms and signs.

An international team of scientists led by those at Imperial College London (UK) recruited 584 adult patients with suspected TB in South Africa and Malawi who were eventually diagnosed with either TB, latent TB infection or another disease, where TB was considered in the differential diagnosis, but then excluded. They took blood samples from these patients and analyzed their blood transcriptional profiles to identify signatures that could be used to calculate a disease risk score capable of differentiating TB from other conditions prevalent in HIV-infected and -uninfected African adults.

The whole blood that was collected before or within 24 hours of commencing TB treatment in suspected patients at the time of recruitment, in PAXgene blood ribonucleic acid (RNA) tubes (PreAnalytiX; Hombrechtikon, Switzerland), frozen within three hours of collection, and later extracted using PAXgene blood RNA kits. RNA was shipped frozen to Singapore for analysis on HumanHT-12 v.4 expression Beadarrays (Illumina; San Diego, CA).

A 27-transcript signature distinguished TB from LTBI and a 44-transcript signature distinguished TB from other diseases. To evaluate the signatures, they used a novel computational method to calculate a disease risk score (DRS) for each patient. The classification based on this score was first evaluated in the test cohort, and then validated in an independent publically available dataset. In the independent validation cohort, the investigators found that patients with TB could be distinguished from patients with latent TB, with a sensitivity of 95% and a specificity of 94%, and from patients with other diseases where the sensitivity was 100% and specificity was 96%.

The authors concludes that from a clinical perspective a simple transcriptome-based test that reliably diagnoses or excludes TB in the majority of patients undergoing investigation for suspected TB. The use of a single blood sample would be of great value, allowing scarce hospital resources to be focused on the small proportion of patients where the result was indeterminate. The challenge is to develop innovative methods to translate multitranscript signatures into simple, cheap tests for TB suitable for use in African health facilities. The study was published on October 22, 2013, in the journal Public Library of Science Medicine.

Related Links:

Imperial College London
PreAnalytiX  
Illumina 



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.